Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

VBI Vaccines has trumpeted top-line data from a trial pitting its hepatitis B virus (HBV) vaccine candidate against GlaxoSmithKline’s Engerix-B – but investors weren’t convinced, and its ...

# A MAN was remanded into custody yesterday after he was accused of robbing two men at gunpoint while they were playing poker on East Street South last week. # Chief Magistrate Roberto Reckley ...

CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ - VBI Vaccines Inc. ("VBI" or the "Company") today announced, that, in connection with its creditor protection proceedings under the Companies ...

STORY HIGHLIGHTS Brii Biosciences acquires BRII-179 assets from VBI Vaccines. The $18 million deal cancels previous agreements and obligations. BRII-179 is in Phase 2 study as a hepatitis B treatment.

VBI Vaccines ( (VBIVQ) ) has shared an announcement.

VBI Vaccines Inc. has completed a restructuring process under the Companies’ Creditors Arrangement Act, resulting in the acquisition by K2 VBI Equity Trust, LLC. All common shares have been ...